Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6) > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):872-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   Freefree

Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):872-6

DOI: 10.23736/S0392-0488.18.06143-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?

Gian Luigi GIOVENE 1 , Luca GIACOMELLI 2, AIDA (Italian Association of Outpatient Dermatologists) Working Group 

1 Private Practitioner, Perugia, Italy; 2 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy



The fixed-combination of Cal/BD aerosol foam is now entering the Italian market. This drug was developed with a technology that allows an enhanced penetration of the active ingredients into the skin. This enhanced penetration improves local bioavailability and, consequently, Cal/BD aerosol foam therapy is associated with improved clinical outcomes if compared with other products with the same components. The efficacy and safety of Cal/BD aerosol foam were confirmed both in clinical trials and in “field-practice” studies. This short review discusses current evidence on the Cal/BD aerosol foam combination; some preliminary data collected in the Italian clinical practice will be also presented.


KEY WORDS: Calcipotriene - Betamethasone dipropionate - Aerosol foam

inizio pagina